Congruence Therapeutics to Participate at the 2023 RBC Capital Markets Healthcare Private Company Conference

MONTREAL, Nov. 30, 2023 /PRNewswire/ -- Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecule correctors for disease, announced today that it will participate in the 2023 RBC Capital Markets Healthcare Private Company Conference, being held in a virtual format December 13-14, 2023.

Clarissa Desjardins, Ph.D., CEO of Congruence, will participate in a fireside chat on Thursday, December 14, 2023, at 9:20 am ET. Company management will also participate in virtual one-on-one meetings with investors at this conference.

About Congruence Therapeutics

Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter.

For more information, please visit www.congruencetx.com.

Company Contact
Charles Grubsztajn
Chief Operating Officer
[email protected]

Media Contact
Amy Conrad
Juniper Point
[email protected] 
858-366-3243

SOURCE Congruence Therapeutics